OBIO Key Statistics, Chart & Performance
The current stock price of OBIO is 4.15 USD. In the past month the price decreased by -13%. In the past year, price decreased by -28.32%.
OBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.11 | 217.86B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.78 | 200.77B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.32 | 141.35B | ||
| SYK | STRYKER CORP | 26.69 | 134.41B | ||
| BDX | BECTON DICKINSON AND CO | 13.46 | 55.39B | ||
| IDXX | IDEXX LABORATORIES INC | 53.65 | 54.02B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.17 | 49.47B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.87 | 37.36B | ||
| RMD | RESMED INC | 24.33 | 35.16B | ||
| DXCM | DEXCOM INC | 35.68 | 25.89B | ||
| PODD | INSULET CORP | 62.2 | 20.00B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.82B |
Related stock screener links
About OBIO
Company Profile
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2020-08-04. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The firm develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Company Info
ORCHESTRA BIOMED HOLDINGS IN
150 Union Square Drive
New Hope PENNSYLVANIA US
Employees: 70
Phone: 16463439298
ORCHESTRA BIOMED HOLDINGS IN / OBIO FAQ
Can you describe the business of ORCHESTRA BIOMED HOLDINGS IN?
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2020-08-04. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The firm develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
What is the stock price of ORCHESTRA BIOMED HOLDINGS IN today?
The current stock price of OBIO is 4.15 USD. The price increased by 0.24% in the last trading session.
What is the dividend status of ORCHESTRA BIOMED HOLDINGS IN?
OBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of OBIO stock?
OBIO has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting OBIO stock to perform?
13 analysts have analysed OBIO and the average price target is 13.84 USD. This implies a price increase of 233.56% is expected in the next year compared to the current price of 4.15.
Can you provide the PE ratio for OBIO stock?
ORCHESTRA BIOMED HOLDINGS IN (OBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.81).
OBIO Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to OBIO. When comparing the yearly performance of all stocks, OBIO is one of the better performing stocks in the market, outperforming 78.4% of all stocks.
OBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OBIO. While OBIO seems to be doing ok healthwise, there are quite some concerns on its profitability.
OBIO Financial Highlights
Over the last trailing twelve months OBIO reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS decreased by -12.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.66% | ||
| ROE | -171.7% | ||
| Debt/Equity | 0.32 |
OBIO Forecast & Estimates
13 analysts have analysed OBIO and the average price target is 13.84 USD. This implies a price increase of 233.56% is expected in the next year compared to the current price of 4.15.
For the next year, analysts expect an EPS growth of -7.65% and a revenue growth 5.88% for OBIO